Abstract Background: Although opioid agonist therapies (OAT) including buprenorphine extended-release (BUP-XR), transmucosal buprenorphine (TM-BUP), methadone and slow-release oral morphine (SROM) are effective and established medications for opioid use disorder (MOUD) available in Canada, differences in opioid-related overdose (OD) risk reduction across OAT types and patterns of treatment use are not well characterized.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Kenneth
Contact Kenneth, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack